Cancer Cells and Metastasis · Journal article

Integrin β1 signaling at the crossroads of cellular plasticity, the tumor microenvironment, and therapy resistance in medulloblastoma

Frontiers in Oncology · August 11, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a narrative mini-review proposing integrin β1 as an underexplored regulator of medulloblastoma progression and therapy resistance by synthesizing developmental, stem cell, and cancer biology literature. The authors acknowledge that direct evidence in MB remains limited and frame the work as a conceptual hypothesis rather than a definitive finding. The clinical relevance of integrin β1 signaling to medulloblastoma outcomes remains speculative pending direct experimental or translational validation.

What was studied

Journal article. Medulloblastoma; pediatric malignant brain tumor.

Key findings

Integrin β1 regulates survival signaling, mechanotransduction, and cancer stem cell maintenance in several tumor types, particularly glioblastoma Tumor–microenvironment interactions contribute to progression, stemness, and therapy resistance in brain cancers Developmental programs, extracellular matrix remodeling, hypoxia, and cancer stem cell plasticity may converge through integrin-dependent signaling in medulloblastoma

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

This review identifies integrin β1 as a potential therapeutic target and mechanistic driver of therapy resistance in medulloblastoma, but clinicians and researchers should recognize this as a conceptual proposal requiring experimental validation before translational or therapeutic development. Direct evidence in medulloblastoma is acknowledged as limited, making this a starting point for hypothesis-driven research rather than actionable clinical guidance.

Plain-language summary

This is a mechanistic mini-review that synthesizes existing literature to propose integrin β1 as a candidate regulator of medulloblastoma progression, without presenting original experimental evidence or clinical data.

Clinical bottom line

Caveats

Authors explicitly state direct evidence in medulloblastoma remains limited
No original experimental or clinical data presented; literature synthesis only
Effect sizes, outcome data, or quantitative evidence not reported
Generalizability from glioblastoma and other tumors to medulloblastoma not empirically tested

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Narrative review; no primary data collection or experimental design reported.

Directness

limited

Discusses integrin β1 in glioblastoma and general cancer biology; direct MB evidence acknowledged as limited.

Consistency

limited

Converging findings cited from multiple fields but no systematic synthesis or quantitative meta-analysis.

Risk of bias

insufficient

Review article; no methodological quality assessment or bias assessment framework described.

Sample adequacy

insufficient

No primary data, no sample size; literature scope not quantified.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Medulloblastoma (MB), the most common malignant pediatric brain tumor, remains associated with relapse and long-term treatment-related toxicities. Tumor–microenvironment interactions increasingly appear to contribute to progression, stemness, and therapy resistance in brain cancers. Integrin β1, a major mediator of cell–extracellular matrix interactions, regulates survival signaling, mechanotransduction, and cancer stem cell maintenance in several tumor types, particularly glioblastoma. This mini-review discusses how developmental programs, extracellular matrix remodeling, hypoxia, and cancer stem cell plasticity may converge through integrin-dependent signaling in MB. Although direct evidence remains limited, converging findings from developmental neurobiology, stem cell biology, and cancer research support integrin β1 as an underexplored candidate regulator of MB progression and therapeutic resistance.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Christopher MontemagnoWilliam EchavidreCancer Cells and MetastasisVincent Picco